Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer ...
ORLANDO, Fla.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous ...
Subcutaneous (SC) administration of medication and fluids for end-of-life cancer care is underutilized in the United States, despite this route having advantages over intravenous (IV) administration, ...
Subcutaneous amivantamab offers a convenient alternative to IV administration for EGFR-mutated NSCLC, reducing infusion-related reactions and administration time. The PALOMA-3 trial confirmed ...
The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback